Opus Historical Balance Sheet
| IRD Stock | 1.05 0.04 3.67% |
Trend analysis of Opus Genetics, balance sheet accounts such as Total Stockholder Equity of 28.8 M or Property Plant And Equipment Net of 0.0 provides information on Opus Genetics,'s total assets, liabilities, and equity, which is the actual value of Opus Genetics, to its prevalent stockholders. By breaking down trends over time using Opus Genetics, balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Opus |
About Opus Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Opus Genetics, at a specified time, usually calculated after every quarter, six months, or one year. Opus Genetics, Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Opus Genetics, and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Opus currently owns. An asset can also be divided into two categories, current and non-current.
Opus Genetics, Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Opus Genetics, assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Opus Genetics, books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Opus Genetics, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Opus Genetics, are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Accounts Payable
An accounting item on the balance sheet that represents Opus Genetics, obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Opus Genetics, are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most accounts from Opus Genetics,'s balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Opus Genetics, current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Opus Genetics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.As of November 28, 2024, Total Assets is expected to decline to about 40.3 M. In addition to that, Total Current Liabilities is expected to decline to about 3.8 M
| 2021 | 2022 | 2023 | 2024 (projected) | Total Current Liabilities | 3.9M | 2.8M | 4.0M | 3.8M | Total Assets | 26.1M | 49.0M | 53.9M | 40.3M |
Opus Genetics, balance sheet Correlations
Click cells to compare fundamentals
Opus Genetics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Opus Genetics, is a strong investment it is important to analyze Opus Genetics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Opus Genetics,'s future performance. For an informed investment choice regarding Opus Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Opus Genetics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics,. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Opus Genetics, is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics,'s value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics,'s market value can be influenced by many factors that don't directly affect Opus Genetics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.